Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Q4 2025 Annual earnings

Reported February 17, 2026 · After market close

Revenue$451.8MBeat by $16.1M
EPS-$0.24Miss by $2.39
Revenue estimate$435.7M
EPS estimate$2.15

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$402.3M
EPS estimate$1.82

Financials

Q4 2025

Income statement

See full
Revenue$451.8M+51.6%
Gross profit$373.0M+45.7%

Balance sheet

See full
Cash & equivalents$136.4M+17.8%
Total debt$2.2B+41.7%
Total equity$48.8M-86.6%
Total assets$2.5B+22.4%

Cash flow

See full
Operating cash flow$219.0M+22.7%
CapEx$1.4M-53.2%
Free cash flow$217.6M+24.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$7.91B+30.1%
Enterprise value$9.96B+32.7%
P/S5.7×-0.3×

Profitability

See full
Gross margin83.6%-0.7pp
FCF margin46.2%0.0pp

Returns & leverage

See full
Debt / equity44.6×+40.4×
Current ratio4.7×-3.1×

Segments

By product

See full
Royalties$258.0M+51.4%
Proprietary product sales$59.6M+25.9%
Bulk rHuPH20 sales$50.2M+155%
Sales-based milestones$25.0M-16.7%
Upfront license and target nomination fees$18.3M—

By geography

See full
All other foreign$8.3M+250%

Versus estimates

Revenue

Q1 2026$376.7MBeat by $18.1M
Q4 2025$451.8MBeat by $16.1M
Q3 2025$354.3MMiss by $92.2MQ2 2025$325.7MMiss by $5.1MQ1 2025$264.9MMiss by $16.1MQ4 2024$298.0MBeat by $12.3M

Diluted EPS

Q1 2026$1.60Beat by $0.06
Q4 2025-$0.24Miss by $2.39
Q3 2025$1.72Beat by $0.09Q2 2025$1.54Beat by $0.31Q1 2025$1.11Beat by $0.16Q4 2024$1.26Beat by $0.09

Ask the moment Halozyme Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Halozyme Therapeutics report Q4 2025 earnings?
Halozyme Therapeutics (HALO) reported Q4 2025 earnings on February 17, 2026 after market close.
What were Halozyme Therapeutics's Q4 2025 revenue and EPS?
Halozyme Therapeutics reported revenue of $451.8M and eps of $-0.24 for Q4 2025.
Did Halozyme Therapeutics beat estimates in Q4 2025?
Revenue beat the consensus estimate of $435.7M by $16.1M. EPS missed the consensus estimate of $2.15 by $2.39.
How did Halozyme Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 51.6% from $298.0M a year earlier.
Where can I find Halozyme Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001159036-26-000023) and the 10-K periodic report (0001159036-26-000024) directly on SEC EDGAR. The filing index links above go to sec.gov.